메뉴 건너뛰기




Volumn 48, Issue 4, 2014, Pages 519-529

Dabrafenib Therapy for Advanced Melanoma

Author keywords

advanced melanoma; BRAF mutation; dabrafenib; GSK2118436; selective BRAF inhibitor; vemurafenib

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ANTIPYRETIC AGENT; B RAF KINASE; CORTICOSTEROID; DABRAFENIB; DACARBAZINE; GAMMA GLUTAMYLTRANSFERASE; IPILIMUMAB; MITOGEN ACTIVATED PROTEIN KINASE; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; RAS PROTEIN; TEMOZOLOMIDE; VEMURAFENIB; ANTINEOPLASTIC AGENT; IMIDAZOLE DERIVATIVE; INDOLE DERIVATIVE; OXIME; SULFONAMIDE;

EID: 84898684848     PISSN: 10600280     EISSN: 15426270     Source Type: Journal    
DOI: 10.1177/1060028013513009     Document Type: Review
Times cited : (27)

References (45)
  • 3
    • 39149104690 scopus 로고    scopus 로고
    • Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials
    • Korn EL,Liu PY,Lee SJ, et al.Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials.J Clin Oncol. 2008;26:527-534.
    • (2008) J Clin Oncol , vol.26 , pp. 527-534
    • Korn, E.L.1    Liu, P.Y.2    Lee, S.J.3
  • 4
    • 79951928689 scopus 로고    scopus 로고
    • Novel mitogen-activated protein kinase inhibitors
    • Chapman MS,Miner JN.Novel mitogen-activated protein kinase inhibitors.Expert Opin Investig Drugs. 2011;20:209-220.
    • (2011) Expert Opin Investig Drugs , vol.20 , pp. 209-220
    • Chapman, M.S.1    Miner, J.N.2
  • 5
    • 18444374405 scopus 로고    scopus 로고
    • Mutations of the BRAF gene in human cancer
    • Davies H,Bignell GR,Cox C, et al.Mutations of the BRAF gene in human cancer.Nature. 2002;417:949-954.
    • (2002) Nature , vol.417 , pp. 949-954
    • Davies, H.1    Bignell, G.R.2    Cox, C.3
  • 6
    • 84864722943 scopus 로고    scopus 로고
    • NRAS mutation status is an independent prognostic factor in metastatic melanoma
    • Jakob JA,Bassett RL,Ng CS, et al.NRAS mutation status is an independent prognostic factor in metastatic melanoma.Cancer. 2012;118:4014-4023.
    • (2012) Cancer , vol.118 , pp. 4014-4023
    • Jakob, J.A.1    Bassett, R.L.2    Ng, C.S.3
  • 7
    • 84978034236 scopus 로고    scopus 로고
    • Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma
    • Long GV,Menzies AM,Nagrial AM, et al.Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma.J Clin Oncol. 2011;29:1239-1246.
    • (2011) J Clin Oncol , vol.29 , pp. 1239-1246
    • Long, G.V.1    Menzies, A.M.2    Nagrial, A.M.3
  • 8
    • 65549130220 scopus 로고    scopus 로고
    • Rnd3 regulation of the actin cytoskeleton promotes melanoma migration and invasive outgrowth in three dimensions
    • Klein RM,Aplin AE.Rnd3 regulation of the actin cytoskeleton promotes melanoma migration and invasive outgrowth in three dimensions.Cancer Res. 2009;69:2224-2233.
    • (2009) Cancer Res , vol.69 , pp. 2224-2233
    • Klein, R.M.1    Aplin, A.E.2
  • 9
    • 78651457445 scopus 로고    scopus 로고
    • Oncogenic BRAF induces melanoma cell invasion by downregulating the cGMP-specific phosphodiesterase PDE5A
    • Arozarena I,Sanchez-Laorden B,Packer L, et al.Oncogenic BRAF induces melanoma cell invasion by downregulating the cGMP-specific phosphodiesterase PDE5A.Cancer Cell. 2011;19:45-57.
    • (2011) Cancer Cell , vol.19 , pp. 45-57
    • Arozarena, I.1    Sanchez-Laorden, B.2    Packer, L.3
  • 10
    • 79959795786 scopus 로고    scopus 로고
    • Improved survival with vemurafenib in melanoma with BRAF V600E mutation
    • Chapman PB,Hauschild A,Robert C, et al.Improved survival with vemurafenib in melanoma with BRAF V600E mutation.N Engl J Med. 2011;364:2507-2516.
    • (2011) N Engl J Med , vol.364 , pp. 2507-2516
    • Chapman, P.B.1    Hauschild, A.2    Robert, C.3
  • 11
    • 84865068182 scopus 로고    scopus 로고
    • Updated overall survival results for BRIM-3, a phase III randomized, open-label, multicenter trial comparing BRAF inhibitor vemurafenib with dacarbazine in previously untreated patients with BRAFV600E-mutated melanoma
    • Chapman PB,Hauschild A,Robert C, et al.Updated overall survival results for BRIM-3, a phase III randomized, open-label, multicenter trial comparing BRAF inhibitor vemurafenib with dacarbazine in previously untreated patients with BRAFV600E-mutated melanoma.J Clin Oncol. 2012;30:.
    • (2012) J Clin Oncol , vol.30
    • Chapman, P.B.1    Hauschild, A.2    Robert, C.3
  • 12
    • 84864285704 scopus 로고    scopus 로고
    • Dabrafenib in BRAF-mutated metastatic melanoma: a multicenter, open-label, phase 3 randomised controlled trial
    • Hauschild A,Grob JJ,Demidov LV, et al.Dabrafenib in BRAF-mutated metastatic melanoma: a multicenter, open-label, phase 3 randomised controlled trial.Lancet. 2012;380:358-365.
    • (2012) Lancet , vol.380 , pp. 358-365
    • Hauschild, A.1    Grob, J.J.2    Demidov, L.V.3
  • 13
    • 84882873880 scopus 로고    scopus 로고
    • An update on BREAK-3, a phase III, randomized trial: dabrafenib versus dacarbazine in patients with BRAF V600E-positive mutation metastatic melanoma
    • Hauschild A,Grob JJ,Demidov LV, et al.An update on BREAK-3, a phase III, randomized trial: dabrafenib versus dacarbazine in patients with BRAF V600E-positive mutation metastatic melanoma.J Clin Oncol. 2013;31:.
    • (2013) J Clin Oncol , vol.31
    • Hauschild, A.1    Grob, J.J.2    Demidov, L.V.3
  • 14
    • 84898680508 scopus 로고    scopus 로고
    • Tafinlar® (Dabrafenib) US prescribing information2013. Research Triangle Park, NC: GlaxoSmithKline, Accessed July 10
    • Tafinlar® (Dabrafenib) US prescribing information2013. Research Triangle Park, NC: GlaxoSmithKline. http://us.gsk.com/products/assets/us_tafinlar.pdfAccessed July 10, 2013.
    • (2013)
  • 15
    • 77956513286 scopus 로고    scopus 로고
    • Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
    • Bollag G,Hirth P,Tsai J, et al.Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma.Nature. 2010;467:596-599.
    • (2010) Nature , vol.467 , pp. 596-599
    • Bollag, G.1    Hirth, P.2    Tsai, J.3
  • 16
    • 74849109743 scopus 로고    scopus 로고
    • Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF
    • Heidorn SJ,Milagre C,Whittaker S, et al.Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF.Cell. 2010;140:209-221.
    • (2010) Cell , vol.140 , pp. 209-221
    • Heidorn, S.J.1    Milagre, C.2    Whittaker, S.3
  • 17
    • 77949732073 scopus 로고    scopus 로고
    • RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
    • Poulikakos PI,Zhang C,Bollag G,Shokat KM,Rosen N.RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF.Nature. 2010;464:427-430.
    • (2010) Nature , vol.464 , pp. 427-430
    • Poulikakos, P.I.1    Zhang, C.2    Bollag, G.3    Shokat, K.M.4    Rosen, N.5
  • 18
    • 77949685981 scopus 로고    scopus 로고
    • RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
    • Hatzivassiliou G,Song K,Yen I, et al.RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth.Nature. 2010;464:431-435.
    • (2010) Nature , vol.464 , pp. 431-435
    • Hatzivassiliou, G.1    Song, K.2    Yen, I.3
  • 19
    • 84898686165 scopus 로고    scopus 로고
    • Research Triangle Park, NC: GlaxoSmithKline
    • Research Triangle Park, NC: GlaxoSmithKline;.
  • 20
    • 84898680506 scopus 로고    scopus 로고
    • Zelboraf® (Vemurafenib) US prescribing information2013. South San Francisco, CA: Genentech USA, Inc. Accessed July 10
    • Zelboraf® (Vemurafenib) US prescribing information2013. South San Francisco, CA: Genentech USA, Inc.http://www.gene.com/download/pdf/zelboraf_prescribing.pdf. Accessed July 10, 2013.
    • (2013)
  • 21
    • 84861083983 scopus 로고    scopus 로고
    • Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumors: a phase 1 dose-escalation trial
    • Falchook GS,Long GV,Kurzrock R, et al.Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumors: a phase 1 dose-escalation trial.Lancet. 2012;379:1893-1901.
    • (2012) Lancet , vol.379 , pp. 1893-1901
    • Falchook, G.S.1    Long, G.V.2    Kurzrock, R.3
  • 22
    • 84891648456 scopus 로고    scopus 로고
    • Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma
    • Accessed August 20 [published online August5, 2013]
    • AsciertoPAMinorDRibasA. Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma [published online August5, 2013]. J Clin Oncol. http://jco.ascopubs.org/content/early/2013/08/05/JCO.2013.49.8691.long. Accessed August 20, 2013.
    • (2013) J Clin Oncol
    • Ascierto, P.A.1    Minor, D.2    Ribas, A.3
  • 23
    • 84868120907 scopus 로고    scopus 로고
    • Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial
    • Long GV,Trefzer U,Davies MA, et al.Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial.Lancet Oncol. 2012;13:1087-1095.
    • (2012) Lancet Oncol , vol.13 , pp. 1087-1095
    • Long, G.V.1    Trefzer, U.2    Davies, M.A.3
  • 24
    • 79953781233 scopus 로고    scopus 로고
    • Prognostic factors for survival in melanoma patients with brain metastases
    • Davies MA,Liu P,McIntyre S, et al.Prognostic factors for survival in melanoma patients with brain metastases.Cancer. 2011;117:1687-1696.
    • (2011) Cancer , vol.117 , pp. 1687-1696
    • Davies, M.A.1    Liu, P.2    McIntyre, S.3
  • 25
    • 2142644507 scopus 로고    scopus 로고
    • Determinants of outcome in melanoma patients with cerebral metastases
    • Fife KM,Coleman MH,Stevens GN, et al.Determinants of outcome in melanoma patients with cerebral metastases.J Clin Oncol. 2004;22:1293-1300.
    • (2004) J Clin Oncol , vol.22 , pp. 1293-1300
    • Fife, K.M.1    Coleman, M.H.2    Stevens, G.N.3
  • 26
    • 44849122610 scopus 로고    scopus 로고
    • Brain and leptomeningeal metastases from cutaneous melanoma: survival outcomes based on clinical features
    • Raizer JJ,Hwu WJ,Pangeas KS, et al.Brain and leptomeningeal metastases from cutaneous melanoma: survival outcomes based on clinical features.Neuro Oncol. 2008;10:199-207.
    • (2008) Neuro Oncol , vol.10 , pp. 199-207
    • Raizer, J.J.1    Hwu, W.J.2    Pangeas, K.S.3
  • 27
    • 0031975369 scopus 로고    scopus 로고
    • Demographics, prognosis, and the therapy in 702 patients with brain metastases from malignant melanoma
    • Sampson JH,Carter JH,Friedman AH,Seigler HF.Demographics, prognosis, and the therapy in 702 patients with brain metastases from malignant melanoma.J Neurosurg. 1998;88:11-20.
    • (1998) J Neurosurg , vol.88 , pp. 11-20
    • Sampson, J.H.1    Carter, J.H.2    Friedman, A.H.3    Seigler, H.F.4
  • 28
    • 84871900504 scopus 로고    scopus 로고
    • Melanoma brain metastases and vemurafenib: need for further investigation
    • Rochet NM,Dronca RS,Kottschade LA, et al.Melanoma brain metastases and vemurafenib: need for further investigation.Mayo Clin Proc. 2012;87:976-981.
    • (2012) Mayo Clin Proc , vol.87 , pp. 976-981
    • Rochet, N.M.1    Dronca, R.S.2    Kottschade, L.A.3
  • 29
    • 84858752302 scopus 로고    scopus 로고
    • An open-label pilot study of vemurafenib in previously treated metastatic melanoma patients with brain metastases
    • Dummer R,Rinderknecht J,Goldinger SM, et al.An open-label pilot study of vemurafenib in previously treated metastatic melanoma patients with brain metastases.J Clin Oncol. 2011;29:.
    • (2011) J Clin Oncol , vol.29
    • Dummer, R.1    Rinderknecht, J.2    Goldinger, S.M.3
  • 30
    • 84873728334 scopus 로고    scopus 로고
    • Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance
    • Das Thakur M,Salangsang F,Landman AS, et al.Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance.Nature. 2013;494:251-255.
    • (2013) Nature , vol.494 , pp. 251-255
    • Das Thakur, M.1    Salangsang, F.2    Landman, A.S.3
  • 31
    • 84869499716 scopus 로고    scopus 로고
    • Successful rechallenge in two patients with BRAF-V600-mutant melanoma who experienced previous progression during treatment with a selective BRAF inhibitor
    • Seghers AC,Wilgenhof S,Lebbé C,Neyns B.Successful rechallenge in two patients with BRAF-V600-mutant melanoma who experienced previous progression during treatment with a selective BRAF inhibitor.Melanoma Res. 2012;22:466-472.
    • (2012) Melanoma Res , vol.22 , pp. 466-472
    • Seghers, A.C.1    Wilgenhof, S.2    Lebbé, C.3    Neyns, B.4
  • 34
    • 84875453915 scopus 로고    scopus 로고
    • Analysis of dermatologic events in vemurafenib-treated patients with melanoma
    • Lacouture ME,Duvic M,Hauschild A, et al.Analysis of dermatologic events in vemurafenib-treated patients with melanoma.Oncologist. 2013;18:314-322.
    • (2013) Oncologist , vol.18 , pp. 314-322
    • Lacouture, M.E.1    Duvic, M.2    Hauschild, A.3
  • 35
    • 84868193136 scopus 로고    scopus 로고
    • Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma
    • Anforth RM,Blumetti TC,Kefford RF, et al.Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma.Br J Dermatol. 2012;167:1153-1160.
    • (2012) Br J Dermatol , vol.167 , pp. 1153-1160
    • Anforth, R.M.1    Blumetti, T.C.2    Kefford, R.F.3
  • 36
    • 84862908097 scopus 로고    scopus 로고
    • RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors
    • Su F,Viros A,Milagre C, et al.RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors.N Engl J Med. 2012;366:207-215.
    • (2012) N Engl J Med , vol.366 , pp. 207-215
    • Su, F.1    Viros, A.2    Milagre, C.3
  • 37
    • 84863116743 scopus 로고    scopus 로고
    • Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib
    • Sosman JA,Kim KB,Schuter L, et al.Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib.N Engl J Med. 2012;366:707-714.
    • (2012) N Engl J Med , vol.366 , pp. 707-714
    • Sosman, J.A.1    Kim, K.B.2    Schuter, L.3
  • 38
    • 84872361487 scopus 로고    scopus 로고
    • Dabrafenib and its potential for the treatment of metastatic melanoma
    • Menzies AM,Long GV,Murali R.Dabrafenib and its potential for the treatment of metastatic melanoma.Drug Des Devel Ther. 2012;6:391-405.
    • (2012) Drug Des Devel Ther , vol.6 , pp. 391-405
    • Menzies, A.M.1    Long, G.V.2    Murali, R.3
  • 39
    • 84857012981 scopus 로고    scopus 로고
    • Novel treatments for metastatic cutaneous melanoma and the management of emergent toxicities
    • Lemech C,Arkenau HT.Novel treatments for metastatic cutaneous melanoma and the management of emergent toxicities.Clin Med Insights Oncol. 2012;6:53-66.
    • (2012) Clin Med Insights Oncol , vol.6 , pp. 53-66
    • Lemech, C.1    Arkenau, H.T.2
  • 40
  • 41
    • 84873823736 scopus 로고    scopus 로고
    • BRAF-targeted therapy for metastatic melanoma: rationale, clinical activity and safety
    • Noor R,Trinh VA,Kim KB,Hwu WJ.BRAF-targeted therapy for metastatic melanoma: rationale, clinical activity and safety.Clin Invest. 2011;1:1127-1139.
    • (2011) Clin Invest , vol.1 , pp. 1127-1139
    • Noor, R.1    Trinh, V.A.2    Kim, K.B.3    Hwu, W.J.4
  • 42
    • 84873819555 scopus 로고    scopus 로고
    • Which drug, and when, for patients with BRAF-mutant melanoma?
    • Jang S,Atkins MB.Which drug, and when, for patients with BRAF-mutant melanoma?.Lancet Oncol. 2013;14:e60-e69.
    • (2013) Lancet Oncol , vol.14
    • Jang, S.1    Atkins, M.B.2
  • 43
    • 84875706825 scopus 로고    scopus 로고
    • Resistance to BRAF-targeted therapy in melanoma
    • Sullivan RJ,Flaherty KT.Resistance to BRAF-targeted therapy in melanoma.Eur J Cancer. 2013;49:1297-1304.
    • (2013) Eur J Cancer , vol.49 , pp. 1297-1304
    • Sullivan, R.J.1    Flaherty, K.T.2
  • 44
    • 84868224906 scopus 로고    scopus 로고
    • Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations
    • Flaherty KT,Infante JR,Daud A, et al.Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations.N Engl J Med. 2012;367:1694-1703.
    • (2012) N Engl J Med , vol.367 , pp. 1694-1703
    • Flaherty, K.T.1    Infante, J.R.2    Daud, A.3
  • 45
    • 84898677747 scopus 로고    scopus 로고
    • National Comprehensive Cancer Network. NCCN Guidelines: melanoma, version 1.2014. Accessed August 20
    • National Comprehensive Cancer Network. NCCN Guidelines: melanoma, version 1.2014. http://www.nccn.org/professionals/physician_gls/pdf/melanoma.pdf. Accessed August 20, 2013.
    • (2013)


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.